Tolerogenic Dendritic Cells On Transplantation: Immunotherapy Based On Second Signal Blockage

dc.creatorSilva
dc.creatorPriscila de Matos; Bier
dc.creatorJulia; Paiatto
dc.creatorLisiery Negrini; Albuquerque
dc.creatorCassia Galdino; Souza
dc.creatorCaique Lopes; Romani Fernandes
dc.creatorLuis Gustavo; da Silva Cunha Tamashiro
dc.creatorWirla Maria; Simioni
dc.creatorPatricia Ucelli
dc.date2015
dc.date2016-06-07T13:33:08Z
dc.date2016-06-07T13:33:08Z
dc.date.accessioned2018-03-29T01:48:52Z
dc.date.available2018-03-29T01:48:52Z
dc.identifier
dc.identifierTolerogenic Dendritic Cells On Transplantation: Immunotherapy Based On Second Signal Blockage. Hindawi Publishing Corp, p. 2015.
dc.identifier2314-8861
dc.identifierWOS:000363575300001
dc.identifier10.1155/2015/856707
dc.identifierhttp://www.hindawi.com/journals/jir/2015/856707/
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/243624
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1307322
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionDendritic cells (DCs), the most important professional antigen-presenting cells (APC), play crucial role in both immunity and tolerance. It is well known that DCs are able to mount immune responses against foreign antigens and simultaneously tolerate self-antigens. Since DCs can be modulated depending on the surrounding microenvironment, they can act as a bridge between innate and adaptive immunity. However, the mechanisms that support this dual role are not entirely clear. Recent studies have shown that DCs can be manipulated ex vivo in order to trigger their tolerogenic profile, what can be a tool to be used in clinical trials aiming the treatment of various diseases and the prevention of transplant rejection. In this sense, the blockage of costimulatory molecules on DC, in the attempt of inhibiting the second signal in the immunological synapse, can be considered as one of the main strategies under development. This review brings an update on current therapies using tolerogenic dendritic cells modulated with costimulatory blockers with the aim of reducing transplant rejection. However, although there are current clinical trials using tolerogenic DC to treat allograft rejection, the actual challenge is to modulate these cells in order to maintain a permanent tolerogenic profile.
dc.description
dc.description
dc.description
dc.description
dc.description
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFAPESP [2013/20258, 2014/08591-0, 2014/16701-0, 2014/08619-2]
dc.description
dc.description
dc.description
dc.languageen
dc.publisherHINDAWI PUBLISHING CORP
dc.publisher
dc.publisherNEW YORK
dc.relationJOURNAL OF IMMUNOLOGY RESEARCH
dc.rightsaberto
dc.sourceWOS
dc.subjectRegulatory T-cells
dc.subjectNatural-killer-cells
dc.subjectAnti-cd40 Monoclonal-antibody
dc.subjectIslet Allograft Survival
dc.subjectSolid-organ Transplantation
dc.subjectDonor-specific Tolerance
dc.subjectVersus-host-disease
dc.subjectNk Cells
dc.subjectHla-g
dc.subjectIn-vivo
dc.titleTolerogenic Dendritic Cells On Transplantation: Immunotherapy Based On Second Signal Blockage
dc.typeArtículos de revistas
dc.typeResumo


Este ítem pertenece a la siguiente institución